Advertisement

Drug Safety

, Volume 41, Issue 12, pp 1411–1411 | Cite as

Comment on “Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis”

  • Katsuhiro Toda
Letter to the Editor

Dear Editor,

The association between proton pump inhibitor (PPI) use and dementia is controversial [1]. In this issue of Drug Safety, Imfeld et al. [2] reported as follows: “As compared to non-use, long-term PPI use (≥ 100 prescriptions) was not associated with an increased risk of developing AD (Alzheimer’s disease) [aOR (adjusted odds ratio) 0.88, 95% CI (confidence interval) 0.80–0.97] or VaD (vascular dementia) (aOR 1.18, 95% CI 1.04–1.33)” [2]. I am afraid that long-term PPI use (≥ 100 prescriptions) was associated with an increased risk of developing VaD (aOR 1.18, 95% CI 1.04–1.33) as compared to non-use based on the results, because the 95% CI was between 1.04 and 1.33.

Notes

Author contributions

Katsuhiro Toda is the only author.

Compliance with Ethical Standards

Funding

No funding was received to assist with the preparation of this letter.

Conflict of interest

Katsuhiro Toda has no conflicts of interest that are directly relevant to the content of this letter.

References

  1. 1.
    Toda K. Are proton pump inhibitors suitable medicine to prevent gastrointestinal events due to non-steroidal anti-inflammatory drugs? J Pharm Prac. 2018;1:5.Google Scholar
  2. 2.
    Imfeld P, Bodmer M, Jick SS, et al. Proton pump inhibitor use and risk of developing Alzheimer’s disease or vascular dementia: a case–control analysis. Drug Saf. 2018.  https://doi.org/10.1007/s40264-018-0704-9 (Epub ahead of print).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Orthopedic SurgeryKitahiroshima Town Toyohira HospitalHiroshimaJapan

Personalised recommendations